Using Liquid Biopsy Testing to Identify, Monitor, Predict Recurrence in Urothelial Carcinoma

Recruiting now

Conditions studied: Urothelial Carcinoma (UC), Bladder (Urothelial, Transitional Cell) Cancer, Liquid Biopsy

In brief

Application of Multi-Component Liquid Biopsy (ctDNA, utDNA, Exosomes, and Protein Biomarkers in Blood and Urine) for Auxiliary Diagnosis, Therapeutic Response Evaluation, and Recurrence Monitoring in Urothelial Carcinoma

Key facts

Study ID

NCT07441499

Run by

Tianjin Medical University Second Hospital

People needed

300

Starts

2026-03-01

Expected to finish

2029-01-01

Last updated by the study team

2026-03-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Suspected or histologically confirmed urothelial carcinoma

You may not qualify if…

• History of or concurrent active malignancy other than urothelial carcinoma

Where it is running

• The second hospital of Tianjin Medical University — Tianjin, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.